Published in Blood on October 24, 2013
Genomics of Hairy Cell Leukemia. J Clin Oncol (2017) 0.75
Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. J Pathol Transl Med (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood (2003) 2.93
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
Is it time to sound an alarm about false-positive cell-free DNA testing for fetal aneuploidy? Am J Obstet Gynecol (2013) 2.33
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol (2007) 1.90
Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 1.69
Coexisting follicular and mantle cell lymphoma with each having an in situ component: A novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma. Am J Clin Pathol (2010) 1.65
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res (2008) 1.48
Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol (2005) 1.43
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2009) 1.42
Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia? Am J Hematol (2002) 1.37
Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood (2003) 1.30
In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica (2011) 1.22
Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn (2007) 1.20
Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol (2002) 1.20
The evolution of molecular genetic pathology: advancing 20th-century diagnostic methods into potent tools for the new millennium. J Mol Diagn (2008) 1.11
Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice. J Mol Diagn (2003) 1.10
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood (2014) 1.10
Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum Mutat (2010) 1.05
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest (2016) 1.05
A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics. Am J Clin Pathol (2011) 1.04
Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr (2009) 1.01
Conditional JAG1 mutation shows the developing heart is more sensitive than developing liver to JAG1 dosage. Am J Hum Genet (2003) 0.96
Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom (2005) 0.96
Primary cardiac lymphoma: utility of multimodality imaging in diagnosis and management. Cancer Biol Ther (2007) 0.94
Intravascular large B-cell lymphoma: a mimicker of many maladies and a difficult and often delayed diagnosis. J Clin Oncol (2010) 0.94
Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Am J Hematol (2008) 0.93
Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol (2008) 0.92
IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Hum Pathol (2009) 0.90
Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genet (2011) 0.89
An interdisciplinary approach to manage cancer cachexia. Clin J Oncol Nurs (2010) 0.88
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer (2012) 0.88
Isolated bowel relapse in acute promyelocytic leukemia: an unusual site of extramedullary recurrence. J Clin Oncol (2010) 0.87
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica (2014) 0.86
Myelodysplastic syndromes. Contemporary biologic concepts and emerging diagnostic approaches. Am J Clin Pathol (2003) 0.85
Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib? Am J Clin Pathol (2008) 0.85
Recurrence of nodal diffuse large B-cell lymphoma as intravascular large B-cell lymphoma: is an intravascular component at initial diagnosis predictive? Arch Pathol Lab Med (2005) 0.85
Functional rules for lac repressor-operator associations and implications for protein-DNA interactions. Protein Sci (2010) 0.84
Lineage ambiguity, infidelity, and promiscuity in immunophenotypically complex acute leukemias: genetic and morphologic correlates. Am J Clin Pathol (2007) 0.84
'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol (2014) 0.83
Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations. Mol Diagn Ther (2012) 0.82
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol (2014) 0.82
CD5-negative, CD10-negative small B-cell leukemia: variant of chronic lymphocytic leukemia or a distinct entity? Am J Hematol (2002) 0.81
Automated screening for myelodysplastic syndromes through analysis of complete blood count and cell population data parameters. Am J Hematol (2014) 0.81
CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol (2007) 0.81
Molecular diagnosis of acute myeloid leukemia. Expert Rev Mol Diagn (2010) 0.81
CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum Pathol (2005) 0.80
Esophageal cancer in a young woman with bulimia nervosa: a case report. J Med Case Rep (2007) 0.80
Molecular diagnostics of acute myeloid leukemia: it's a (next) generational thing. J Mol Diagn (2012) 0.79
A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma. Cancer Genet Cytogenet (2007) 0.79
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Cancer Biol Ther (2007) 0.79
The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights. Hematology (2006) 0.79
Genetics of diffuse large B-cell lymphoma: paving a path to personalized medicine. Cancer J (2014) 0.79
Expanded populations of surface membrane immunoglobulin light chain-negative B cells in lymph nodes are not always indicative of B-cell lymphoma. Am J Clin Pathol (2005) 0.79
Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. J Mol Diagn (2008) 0.78
Primary ductal adenocarcinoma of the lacrimal gland. Ophthalmology (2005) 0.78
Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. Expert Rev Mol Diagn (2011) 0.78
Risk Factors Associated with Unplanned Hospital Readmissions in Adults with Cancer. Oncol Nurs Forum (2015) 0.77
Molecular genetic characterization of lymphoma: application to cytology diagnosis. Diagn Cytopathol (2012) 0.77
Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed-Sternberg cell. Expert Rev Mol Diagn (2007) 0.77
Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies. Clin Lab Med (2011) 0.77
ZAP70 expression assessed by immunohistochemistry on peripheral blood: a simple prognostic assay for patients with chronic lymphocytic leukemia. Appl Immunohistochem Mol Morphol (2007) 0.77
Aggressive Epstein-Barr virus-associated, CD8+, CD30+, CD56+, surface CD3-, natural killer (NK)-like cytotoxic T-cell lymphoma. Am J Surg Pathol (2002) 0.76
Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma. J Cutan Pathol (2009) 0.76
Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. Appl Immunohistochem Mol Morphol (2010) 0.76
An alternative spliced RNASEL variant in peripheral blood leukocytes. J Interferon Cytokine Res (2006) 0.76
Hodgkin lymphoma: pathology, pathogenesis, and a plethora of potential prognostic predictors. Adv Anat Pathol (2014) 0.76
Posttransplantation lymphoproliferative disease involving the pituitary gland. Hum Pathol (2010) 0.76
T cell receptor gamma-chain gene polymerase chain reaction to diagnose central nervous system involvement by cutaneous T cell lymphoma. J Mol Diagn (2002) 0.75
α-Hemoglobin-stabilizing protein is a sensitive and specific marker of erythroid precursors. Am J Surg Pathol (2012) 0.75
The role of molecular pathology in the diagnosis of cutaneous lymphomas. Patholog Res Int (2012) 0.75
Igbeta(CD79b) mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. Am J Hematol (2007) 0.75
Making a meal of multiple mutations in acute myeloid malignancies. J Mol Diagn (2011) 0.75
Transient blood transfusion reaction masquerading as a post-transplantation lymphoproliferative disorder mimicking acute leukemia cutis. J Clin Oncol (2011) 0.75
Improvement of pancytopenia and thrombocytopenia with decreasing mosaicism for isochromosome Xp. Pediatr Blood Cancer (2009) 0.75
Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy. Blood (2014) 0.75
Hyperdiploidy with trisomy 9 and deletion of the CDKN2A locus in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet (2009) 0.75
Images Dx. Severe babesiosis. J Hosp Med (2010) 0.75
Reactive versus neoplastic lymphoid follicles: proliferation and death versus quiescence and staying alive. Br J Haematol (2004) 0.75
8p21 microdeletion in a patient with intellectual disability and behavioral abnormalities. Am J Med Genet A (2011) 0.75
Bringing an inpatient palliative care program to a teaching hospital: lessons in leadership. Oncol Nurs Forum (2007) 0.75
Unusual hematologic malignancies. Case 1. Hematologic malignancy presenting with diarrhea and bony lesions: systemic mastocytosis. J Clin Oncol (2002) 0.75
Toward a therapeutically relevant, molecularly based classification of lymphoma: are we there yet? Am J Clin Pathol (2007) 0.75
Accomplishing much in a short time: use of a rapid improvement event to redesign the assessment and treatment of patients with alcohol withdrawal. Am J Med Qual (2012) 0.75
Hereditary elliptocytosis. Blood (2013) 0.75
The basis and rational use of molecular genetic testing in mature B-cell lymphomas. Adv Anat Pathol (2010) 0.75
CLL/SLL diagnosed in an adolescent. Pediatr Blood Cancer (2013) 0.75
Large B-cell lymphoma masquerading as acute leukemia. J Clin Oncol (2006) 0.75
A 2020 Vision Into Hodgkin Lymphoma Biology. Adv Anat Pathol (2020) 0.75
Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoid X receptor agonist, bexarotene. Leuk Lymphoma (2011) 0.75
Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies. Expert Opin Med Diagn (2009) 0.75
Crystal-storing histiocytosis in plasma cell myeloma. Am J Hematol (2010) 0.75
Circulating CD30-positive T-cell lymphoma with anaplastic morphology. Blood (2016) 0.75